The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Antimyelin Antibodies as a Predictor of Clinically Definite Multiple Sclerosis after a First Demyelinating Event
Open accessAbstract
BACKGROUND: Most patients with multiple sclerosis initially present with a clinically isolated syndrome. Despite the fact that clinically definite multiple sclerosis will develop in up to 80 percent of these patients, the course of the disease is unpredictable at its onset and requires long-term observation or repeated magnetic resonance imaging (MRI). We investigated whether the presence of serum antibodies against myelin oligodendrocyte glycoprotein (MOG) and myelin basic protein (MBP) in patients with a clinically isolated syndrome predicts the interval to conversion to clinically definite multiple sclerosis. METHODS: A total of 103 patients with a clinically isolated syndrome, positive findings on cerebral MRI, and oligoclonal bands in the cerebrospinal fluid were studied. At base line, serum samples were collected to test for anti-MOG and anti-MBP antibodies with Western blot analysis, and the lesions detected by cerebral MRI were quantified. Neurologic examinations for relapse or disease progression (defined as conversion to clinically definite multiple sclerosis) were performed at base line and subsequently every three months. RESULTS: Patients with anti-MOG and anti-MBP antibodies had relapses more often and earlier than patients without these antibodies. Only 9 of 39 antibody-seronegative patients (23 percent) had a relapse, and the mean (+/-SD) time to relapse was 45.1+/-13.7 months. In contrast, 21 of 22 patients (95 percent) with antibodies against both MOG and MBP had a relapse within a mean of 7.5+/-4.4 months, and 35 of 42 patients (83 percent) with only anti-MOG antibodies had a relapse within 14.6+/-9.6 months (P<0.001 for both comparisons with antibody-seronegative patients). The adjusted hazard ratio for the development of clinically definite multiple sclerosis was 76.5 (95 percent confidence interval, 20.6 to 284.6) among the patients who were seropositive for both antibodies and 31.6 (95 percent confidence interval, 9.5 to 104.5) among the patients who were seropositive only for anti-MOG antibodies, as compared with the seronegative patients. CONCLUSIONS: Analysis of antibodies against MOG and MBP in patients with a clinically isolated syndrome is a rapid, inexpensive, and precise method for the prediction of early conversion to clinically definite multiple sclerosis. This finding may be important for the counseling and care of patients with a first demyelinating event suggestive of multiple sclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1032 · Cited by 6,969
Axonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
Noseworthy, J. H., Lucchinetti, C., Rodriguez, M., & Weinshenker, B. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431307 · Cited by 2,899
Jacobs, L. D., Beck, R. W., Simon, J. H., Kinkel, R. P., Brownscheidle, C. M., Murray, T. J., Simonian, N. A., Slasor, P. J., & Sandrock, A. W. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431301 · Cited by 1,501
Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen
Lehmann, P. V., Forsthuber, T., Miller, A., & Sercarz, E. E. (1992) · Nature · doi:10.1038/358155a0 · Cited by 1,186
Comi, G., Filippi, M., Barkhof, F., Durelli, L., Edan, G., Fernández, O., Hartung, H.-P., Seeldrayers, P., Sørensen, P. S., Rovaris, M., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04725-5 · Cited by 1,053
Epitope spreading in immune-mediated diseases: implications for immunotherapy
Vanderlugt, C. L., & Miller, S. D. (2002) · Nature Reviews Immunology · doi:10.1038/nri724 · Cited by 950
Identification of autoantibodies associated with myelin damage in multiple sclerosis
Genain, C. P., Cannella, B., Hauser, S. L., & Raine, C. S. (1999) · Nature Medicine · doi:10.1038/5532 · Cited by 892
A longitudinal study of abnormalities on MRI and disability from multiple sclerosis
Brex, P. A., Ciccarelli, O., O'Riordan, J. I., Sailer, M., Thompson, A. J., & Miller, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011341 · Cited by 861
Distinct Patterns of Multiple Sclerosis Pathology Indicates Heterogeneity in Pathogenesis
Lucchinetti, C. F., Brück, W., Rodriguez, M., & Lassmann, H. (1996) · Brain Pathology · doi:10.1111/j.1750-3639.1996.tb00854.x · Cited by 733
Linington, C., Bradl, M., Lassmann, H., Brunner, C., & Vass, K. (1988) · PubMed · Cited by 708
WEINSHENKER, B. G., BASS, B., RICE, G. P. A., NOSEWORTHY, J., CARRIERE, W., BASKERVILLE, J., & EBERS, G. C. (1989) · Brain · doi:10.1093/brain/112.6.1419 · Cited by 602
Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up
Runmarker, B., & Andersen, O. (1993) · Brain · doi:10.1093/brain/116.1.117 · Cited by 568
The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up
O'Riordan, J. (1998) · Brain · doi:10.1093/brain/121.3.495 · Cited by 484
Multiple sclerosis: In situ evidence for antibody‐ and complement‐mediated demyelination
Storch, M. K., Piddlesden, S., Haltia, M., Iivanainen, M., Morgan, P., & Lassmann, H. (1998) · Annals of Neurology · doi:10.1002/ana.410430409 · Cited by 422
Brunner, C., Lassmann, H., Waehneldt, T. V., Matthieu, J., & Linington, C. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb10930.x · Cited by 409
Patterns of oligodendroglia pathology in multiple sclerosis
Ozawa, K., Suchanek, G., Breitschopf, H., Br€ck, W., Budka, H., Jellinger, K., & Lassmann, H. (1994) · Brain · doi:10.1093/brain/117.6.1311 · Cited by 404
Link, H., & Tibbling, G. (1977) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365517709091498 · Cited by 372
Fazekas, F., Offenbacher, H., Fuchs, S., Schmidt, R., Niederkorn, K., Horner, S., & Lechner, H. (1988) · Neurology · doi:10.1212/wnl.38.12.1822 · Cited by 350
Reindl, M., Linington, C., Brehm, U., Egg, R., Dilitz, E., Deisenhammer, F., Poewe, W., & Berger, T. (1999) · Brain · doi:10.1093/brain/122.11.2047 · Cited by 347
Self-citationDalton, C. M., Brex, P. A., Miszkiel, K. A., Hickman, S. J., MacManus, D. G., Plant, G. T., Thompson, A. J., & Miller, D. H. (2002) · Annals of Neurology · doi:10.1002/ana.10240 · Cited by 290
Yu, M., Johnson, J. M., & Tuohy, V. K. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.4.1777 · Cited by 266
Adelmann, M., Wood, J., Benzel, I., Fiori, P., Lassmann, H., Matthieu, J.-M., Gardinier, M. V., Dornmair, K., & Linington, C. (1995) · Journal of Neuroimmunology · doi:10.1016/0165-5728(95)00124-7 · Cited by 232
Management of Multiple Sclerosis
Rudick, R. A., Cohen, J. A., Weinstock-Guttman, B., Kinkel, R. P., & Ransohoff, R. M. (1997) · New England Journal of Medicine · doi:10.1056/nejm199711273372207 · Cited by 201
de Rosbo, N. K., Honegger, P., Lassmann, H., & Matthieu, J. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb04173.x · Cited by 166
Goebels, N. (2000) · Brain · doi:10.1093/brain/123.3.508 · Cited by 165
Stefferl, A., Brehm, U., Storch, M. K., Lambracht‐Washington, D., Bourquin, C., Wonigeit, K., Lassmann, H., & Linington, C. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.1.40 · Cited by 143
Anti-MOG and anti-MBP antibody subclasses in multiple sclerosis
Egg, R., Reindl, M., Deisenhammer, F., Linington, C., & Berger, T. (2001) · Multiple Sclerosis Journal · doi:10.1177/135245850100700503 · Cited by 116
Self-citationvon Büdingen, H. ‐., Hauser, S. L., Fuhrmann, A., Nabavi, C. B., Lee, J. I., & Genain, C. P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122092499 · Cited by 96
Jacobs, L. D., Kaba, S. E., Miller, C., Priore, R. L., & Brownscheidle, C. M. (1997) · Annals of Neurology · doi:10.1002/ana.410410315 · Cited by 90
Multiple Sclerosis—From Probable to Definite Diagnosis: A 7-Year Prospective Study
Achiron, A., & Barak, Y. (2000) · Archives of Neurology · doi:10.1001/archneur.57.7.974 · Cited by 75
McFarland, H. I., Lobito, A. A., Johnson, M. M., Nyswaner, J. T., Frank, J. A., Palardy, G. R., Tresser, N. J., Genain, C. P., Mueller, J. P., Matis, L. A., et al. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.4.2384 · Cited by 73
Brück, W., Neubert, K., Berger, T., & Weber, J. R. (2001) · Multiple Sclerosis Journal · doi:10.1177/135245850100700307 · Cited by 42
Self-citation
Cited by
Immunology of multiple sclerosis
Sospedra, M., & Martin, R. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115707 · Cited by 2,149
Multiple sclerosis: a complicated picture of autoimmunity
McFarland, H. F., & Martin, R. (2007) · Nature Immunology · doi:10.1038/ni1507 · Cited by 985
Multiple Sclerosis: Mechanisms and Immunotherapy
Baecher-Allan, C., Kaskow, B. J., & Weiner, H. L. (2018) · Neuron · doi:10.1016/j.neuron.2018.01.021 · Cited by 938
Myelin oligodendrocyte glycoprotein antibodies in neurological disease
Reindl, M., & Waters, P. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0112-x · Cited by 626
Self-citationMiller, D., Barkhof, F., Montalban, X., Thompson, A., & Filippi, M. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70071-5 · Cited by 594
Metadata
- Authors
- Berger, T., Rubner, P., Schautzer, F., Egg, R., Ulmer, H., Mayringer, I., Dilitz, E., Deisenhammer, F., & Reindl, M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-07-10
- Volume
- 349
- Issue
- 2
- Pages
- 139-145
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2074074558
- Cited by
- 616
- References
- 34
- FWCI
- 33.05
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.